相关实验视频

Updated: Jun 29, 2025

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

抗ferroptosis治疗缓解了动脉样硬化的发展

Zhou Yang^1,2,3,4, Yue He^5,6,7, Dejun Wu⁸

¹Department of Vascular Surgery Shanghai Pudong Hospital Fudan University Pudong Medical Center Shanghai China.

|April 5, 2024

概括

铁亡,细胞死亡过程,与动脉样硬化 (AS) 有关. 氧化LDL通过抑制GPX4诱导铁亡,从而导致AS的进展. 抑制铁亡对治疗AS及其相关疾病有很大的希望.

科学领域:

生物医学研究的研究.
心血管病理学心血管病理学
细胞生物学细胞生物学

背景情况:

铁亡与各种疾病有关,但其在动脉样硬化 (AS) 病原发生中的作用尚未完全理解.
动脉样硬化涉及复杂的病理阶段,包括内皮细胞损伤,单细胞粘附和泡细胞形成.
氧化低密度脂蛋白 (ox-LDL) 是AS发展的关键因素.

研究的目的:

阐明铁死在动脉样硬化的关键病理阶段中的作用.
研究ox-LDL在内皮细胞中诱导铁亡的机制.
评估AS模型中抑制铁亡的治疗潜力.

主要方法:

研究了内皮细胞中的铁,单细胞粘附和泡细胞的形成.
评估了ox-LDL对铁和谷氨过氧化酶4 (GPX4) 活性的影响.
利用高脂肪饮食诱导的动脉样的小鼠模型.
在体内给予铁灭抑制剂以评估治疗效果.

主要成果:

证实Ox-LDL通过抑制GPX4活性在内皮细胞中强烈诱导铁亡.
抑制铁亡减少单细胞粘附和内皮细胞炎症.
发现铁性调节巨细胞中的胆固醇排放,影响泡细胞的形成.
在体内研究表明,高脂肪饮食诱导铁亡,高脂血症和AS病变,这些病变被铁亡抑制剂改善.

结论:

氧化低密度脂蛋白通过抑制GPX4活性诱导铁亡,从而导致动脉样硬化进展.
抑制铁灭症在体内显示出对动脉样硬化有显著的治疗潜力.
与铁亡相关的生物标志物显示出对动脉样硬化的诊断有前途.

关键词:

动脉样硬化动脉样硬化内皮细胞是内皮细胞.铁性化 (ferroptosis) 是一种谷氨过氧化酶4的作用氧化低密度脂蛋白是一种氧化低密度脂蛋白.

更多相关视频

Quantification of Atherosclerosis in Mice

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Inflammation

Inflammation

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...